Trials / Completed
CompletedNCT01666795
Autoantibody Specificity and Response to IVIG in ITP
Autoantibody Specificity and Response to Intravenous Immunoglobulin G (IVIG) in Immune Thrombocytopenia (ITP): a Retrospective Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 672 (actual)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
Detailed description
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder, in which platelet surface GPIIb/IIIa and GPIb/IX are the two most frequently targeted autoantigens. Our previous studies in animal models of ITP demonstrated that intravenous immunoglobulin G (IVIG) could protect against anti-GPIIb/IIIa-mediated thrombocytopenia but failed to ameliorate ITP induced by most anti-GPIb/IX antibodies. The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
Conditions
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2013-01-01
- Completion
- 2014-01-01
- First posted
- 2012-08-16
- Last updated
- 2016-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01666795. Inclusion in this directory is not an endorsement.